Radiotherapy Alternates Human Epidermal Growth Factor 2 (Her2) Expression in Human Breast Cancer

Based on fundamental study （in Vitro and in Vivo, Pro. Jianjian Li）， Her2 expression would be changed from negative to positive by cancer irradiation with liner-accelerator at dose 6GY or up. The propose of this study is to reveal the irradiation result on Her2 expression in human breast cancer.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Human Epidermal Growth Factor 2 Negative Carcinoma of Breast Neoplasms

Age range

18 year–80 year

Sex eligibility

Female

Study type

Observational

Primary location

Qingdao Central Hospital, Qingdao Cancer Hospital

Qingdao, Shandong, 266042, China

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

histological confirmed advanced breast cancer
cancer sample can be obtained by fine needle biopsy
IHC and FISH confirmed Her2 negative
radiotherapy indication for local residual cancer

Exclusion criteria

no radiotherapy indication
patient refuse

Treatment and study plan

Primary outcomes

Her2 changes during radiotherapy

Time frame: every week up to 6 weeks

biopsy is obtained by fine needle biopsy，Her2 is checked by Immunohistochemistry (IHC) and Fluorescence in situ hybridization (FISH).

Sponsors and collaborators

Lead sponsor

Qingdao Central Hospital

Other

Registry information

Official study title

Study on Human Epidermal Growth Factor 2 (Her2) Expression Changes in Human Breast Cancer After Radiotherapy

Important dates

Study start: 2013
Primary completion: 2022
Study completion: 2022
First posted: Sep 4, 2013
Registry last updated: Mar 29, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed